Verici Dx plc (VRCDF)
OTCMKTS
· Delayed Price · Currency is USD
0.0300
0.00 (0.00%)
Jul 4, 2025, 4:00 PM EDT
Verici Dx Revenue
In the year 2024, Verici Dx had annual revenue of $3.34M with 229.62% growth.
Revenue
3.34M
Revenue Growth
+229.62%
P/S Ratio
1.11
Revenue / Employee
185.50K
Employees
14
Market Cap
3.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.34M | 2.33M | 229.62% |
| Dec 31, 2023 | 1.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 84.04M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Verici Dx News
- 7 weeks ago - AIM Market Roundup: Belluscura, Tiger Royalties, ITM Power - The Armchair Trader
- 3 months ago - AIM Market Roundup: Ethernity Networks, Verici DX, Aferian - The Armchair Trader
- 3 months ago - AIM Market Roundup: Rome Resources, Celadon Pharmaceuticals, Churchill China - The Armchair Trader
- 3 months ago - AIM Market Roundup: Celadon Pharma, Oracle Power, Volex - The Armchair Trader
- 7 months ago - FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians - Business Wire